Biopharma News

Aug 18, 2017
By BioPharm International Editors
FDA approves new molecular entity developed by Pfizer for treating a rare form of leukemia in adults.
Aug 16, 2017
By BioPharm International Editors
The US Patent and Trademark Office issued three new patents that extend protection for Alexion’s rare-disease drug, Soliris, for an additional 10 years.
Aug 16, 2017
By BioPharm International Editors
A research collaboration joins Aslan with an academic research institute for studying small-molecule cancer drug candidates.
Aug 15, 2017
By BioPharm International Editors
The antibody therapeutic failed to meet its primary endpoint in a Phase III study.
Aug 10, 2017
By BioPharm International Editors
Pfizer will invest $100 million to expand its manufacturing facilities in Sanford, North Carolina.
Aug 09, 2017
By BioPharm International Editors
Through its life-sciences business, MilliporeSigma, Merck KGaA will collaborate with Baylor College of Medicine to advance vaccine development for neglected and emerging diseases.
Aug 09, 2017
By BioPharm International Editors
FDA requests more detailed information on a post-marketing study for Dynavax’s hep-B vaccine, which will require an extended review time past its August 2017 PDUFA date.
Aug 07, 2017
By BioPharm International Editors
The Washington-headquartered biotech firm plans to use the newly purchased facility to produce antibodies for its current and future pipeline.
Aug 07, 2017
BioPharm International
By BioPharm International Editors
On August 3, 2017, Bristol-Myers Squibb (BMS) announced that it has agreed to acquire biotech firm, IFM Therapeutics, in a deal worth over $1 billion to develop BMS’ oncology pipeline.
Aug 04, 2017
By BioPharm International Editors
FDA has approved Mavyret (glecaprevir and pibrentasvir), a new molecular entity (NME), to treat chronic hepatitis C virus (HCV).
native1_300x100
lorem ipsum